We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can MEDP's Record Q2 Bookings Build a Stronger Growth Path for 2027?
Read MoreHide Full Article
Key Takeaways
Medpace posted record Q2 net new business awards of $795.7 million, lifting book-to-bill to 1.13.
MEDP's backlog reached $3.01 billion, with about $1.96 billion expected to convert within 12 months.
MEDP's record bookings were helped by lower cancellations, which remain difficult to forecast.
Medpace Holdings, Inc. (MEDP - Free Report) regained commercial momentum in the second quarter of 2026 as record awards and a higher book-to-bill ratio reversed the weaker first-quarter trend.
The central issue is timing. Better demand can strengthen backlog and support future growth, but study starts, pre-backlog work and unpredictable cancellations may delay the larger revenue benefit until 2027.
MEDP Delivers Record Quarterly Awards
Net new business awards increased 28.2% year over year to $795.7 million, the highest quarterly level reported by Medpace. The result lifted net book-to-bill to 1.13, meaning awards exceeded second-quarter revenues.
That was a clear improvement from the first quarter's 0.88 ratio. The rebound indicates that commercial activity recovered enough to replace revenue consumed during the quarter and begin rebuilding forward coverage.
Medpace’s Demand Indicators Broaden
Request-for-proposal activity increased both sequentially and year over year, while win rates recovered after management's improvement initiatives. Client funding activity also remained constructive, supporting a broader opportunity set.
Management expects gross bookings to ramp during the second half. That outlook is relevant across the contract research market, where ICON plc (ICLR - Free Report) provides integrated clinical development services and IQVIA Holdings Inc. (IQV - Free Report) combines clinical research services with healthcare data and analytics. For MEDP, stronger gross awards will matter most if cancellations stay within a reasonable range.
MEDP’s Oncology Mix Reshapes the Pipeline
Oncology represented more than half of second-quarter bookings and initial award notifications. At the same time, new cardiometabolic award activity moderated as several large metabolic programs moved closer to maturity.
The shift reduces reliance on the therapeutic area that recently drove growth and moves the pipeline toward Medpace's historical mix. Yet oncology programs can carry different award, study-start and conversion patterns, leaving the timing of revenue recognition less predictable.
Medpace’s Backlog Supports Revenue Continuity
Ending backlog increased 4.9% year over year to $3.01 billion. Medpace expects approximately $1.96 billion of that backlog to convert into revenues over the next 12 months, providing a meaningful base of contracted work.
The near-term conversion estimate does not capture the full potential of the second-quarter awards. Some programs remain in pre-backlog, while others need additional time before study activity begins. Those lags could push much of the incremental contribution into 2027.
Here's where the consensus estimates for the company's 2026 and 2027 sales currently stand.
Image Source: Zacks Investment Research
MEDP’s Cancellation Risk Clouds the Recovery
Lower cancellations accounted for more than half of the sequential improvement in net bookings. That makes the quarterly record less straightforward than the headline figure suggests because part of the rebound came from fewer lost awards rather than gross-booking growth alone.
Management said cancellations cannot be forecast reliably and may arise without warning. A renewed spike could weaken net bookings, slow backlog expansion and delay the expected benefit from the stronger commercial pipeline.
MEDP’s Growth Signals Support Cautious Optimism
The second-quarter recovery improves MEDP's path toward stronger 2027 growth, but execution still depends on converting awards into backlog and starting studies on schedule. The year-to-date book-to-bill ratio of 1.00 also shows that the first-half recovery was balanced rather than decisive.
Image Source: Zacks Investment Research
MEDP currently carries a Zacks Rank #2 (Buy), with a Growth Score of A and a VGM Score of B. Those readings support the stock's growth profile and complement its favorable earnings-revision signal. Still, a Value Score of D and a Momentum Score of C argue for close attention to valuation, backlog conversion and the durability of bookings before drawing a firmer conclusion.
View the Zacks #1 Rank List
Image: Bigstock
Can MEDP's Record Q2 Bookings Build a Stronger Growth Path for 2027?
Key Takeaways
Medpace Holdings, Inc. (MEDP - Free Report) regained commercial momentum in the second quarter of 2026 as record awards and a higher book-to-bill ratio reversed the weaker first-quarter trend.
The central issue is timing. Better demand can strengthen backlog and support future growth, but study starts, pre-backlog work and unpredictable cancellations may delay the larger revenue benefit until 2027.
MEDP Delivers Record Quarterly Awards
Net new business awards increased 28.2% year over year to $795.7 million, the highest quarterly level reported by Medpace. The result lifted net book-to-bill to 1.13, meaning awards exceeded second-quarter revenues.
That was a clear improvement from the first quarter's 0.88 ratio. The rebound indicates that commercial activity recovered enough to replace revenue consumed during the quarter and begin rebuilding forward coverage.
Medpace’s Demand Indicators Broaden
Request-for-proposal activity increased both sequentially and year over year, while win rates recovered after management's improvement initiatives. Client funding activity also remained constructive, supporting a broader opportunity set.
Management expects gross bookings to ramp during the second half. That outlook is relevant across the contract research market, where ICON plc (ICLR - Free Report) provides integrated clinical development services and IQVIA Holdings Inc. (IQV - Free Report) combines clinical research services with healthcare data and analytics. For MEDP, stronger gross awards will matter most if cancellations stay within a reasonable range.
MEDP’s Oncology Mix Reshapes the Pipeline
Oncology represented more than half of second-quarter bookings and initial award notifications. At the same time, new cardiometabolic award activity moderated as several large metabolic programs moved closer to maturity.
The shift reduces reliance on the therapeutic area that recently drove growth and moves the pipeline toward Medpace's historical mix. Yet oncology programs can carry different award, study-start and conversion patterns, leaving the timing of revenue recognition less predictable.
Medpace’s Backlog Supports Revenue Continuity
Ending backlog increased 4.9% year over year to $3.01 billion. Medpace expects approximately $1.96 billion of that backlog to convert into revenues over the next 12 months, providing a meaningful base of contracted work.
The near-term conversion estimate does not capture the full potential of the second-quarter awards. Some programs remain in pre-backlog, while others need additional time before study activity begins. Those lags could push much of the incremental contribution into 2027.
Here's where the consensus estimates for the company's 2026 and 2027 sales currently stand.
Image Source: Zacks Investment Research
MEDP’s Cancellation Risk Clouds the Recovery
Lower cancellations accounted for more than half of the sequential improvement in net bookings. That makes the quarterly record less straightforward than the headline figure suggests because part of the rebound came from fewer lost awards rather than gross-booking growth alone.
Management said cancellations cannot be forecast reliably and may arise without warning. A renewed spike could weaken net bookings, slow backlog expansion and delay the expected benefit from the stronger commercial pipeline.
MEDP’s Growth Signals Support Cautious Optimism
The second-quarter recovery improves MEDP's path toward stronger 2027 growth, but execution still depends on converting awards into backlog and starting studies on schedule. The year-to-date book-to-bill ratio of 1.00 also shows that the first-half recovery was balanced rather than decisive.
Image Source: Zacks Investment Research
MEDP currently carries a Zacks Rank #2 (Buy), with a Growth Score of A and a VGM Score of B. Those readings support the stock's growth profile and complement its favorable earnings-revision signal. Still, a Value Score of D and a Momentum Score of C argue for close attention to valuation, backlog conversion and the durability of bookings before drawing a firmer conclusion.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.